AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

ClinicalTrials.gov ID: NCT06137118

Public ClinicalTrials.gov record NCT06137118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study will consist of 4 parts. Part A: monotherapy dose escalation in 3L+ B-ALL. Part B: dose optimization in 3L+ B-ALL. Part C: Dose expansion in 3L+ B-ALL. Part D: Dose optimization and efficacy expansion in R/R B-ALL (2L+)

Study identification

NCT ID: NCT06137118
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 255 participants

Conditions and interventions

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

Surovatamig Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 28, 2023
Primary completion: Feb 10, 2028
Completion: Sep 14, 2028
Last update posted: Aug 18, 2026

2023 – 2028

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35205	Withdrawn
Research Site	Duarte	California	91010	Recruiting
Research Site	Los Angeles	California	90048	Recruiting
Research Site	Palo Alto	California	94304	Recruiting
Research Site	Tampa	Florida	33612	Recruiting
Research Site	Atlanta	Georgia	30322	Recruiting
Research Site	Chicago	Illinois	60637	Recruiting
Research Site	New York	New York	10016	Recruiting
Research Site	Houston	Texas	77030	Recruiting
Research Site	Richmond	Virginia	23298	Recruiting
Research Site	Seattle	Washington	98109	Withdrawn
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06137118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06137118 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →